Jenny Klinger, MBA

Jenny Klinger joined Foghorn Therapeutics in 2024 as VP, Financial Planning & Analysis.

Jenny joined Foghorn from Disc Medicine, where she was Head of Financial Planning & Analysis. While at Disc Medicine, she was part of its transition from a Series B company to a public company, raising $0.6B within two years. Previously, she held roles of increasing responsibility in finance and forecasting from early clinical stage through commercialization at Seres Therapeutics, Sanofi Genzyme, Epizyme, FORUM Pharmaceuticals and Biogen. She has extensive experience with commercial readiness and launches, including KEVZARA^® at Sanofi Genzyme and TECFIDERA^®, ALPROLIX^®, ELOCTATE^® and PLEGRIDY^® at Biogen. Before working in biotech, Jenny worked at Mass General Brigham primarily on strategic acquisitions, including Neighborhood Health Plan (now Mass General Brigham Health Plan), Goldman Sachs and in Transaction Services at KPMG.

Jenny received an MBA from the Kellogg School of Management at Northwestern University, an MS in Accountancy from the University of Illinois Urbana-Champaign and a BA in Economics from Providence College. She is an Illinois-licensed CPA.